UniProt ID | PARK7_RAT | |
---|---|---|
UniProt AC | O88767 | |
Protein Name | Protein/nucleic acid deglycase DJ-1 {ECO:0000250|UniProtKB:Q99497} | |
Gene Name | Park7 {ECO:0000312|RGD:621808} | |
Organism | Rattus norvegicus (Rat). | |
Sequence Length | 189 | |
Subcellular Localization |
Cell membrane Lipid-anchor . Cytoplasm . Membrane raft . Nucleus . Mitochondrion . Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subs |
|
Protein Description | Protein and nucleotide deglycase that catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals. Thus, functions as a protein deglycase that repairs methylglyoxal- and glyoxal-glycated proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteine, arginine and lysine residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) that cause irreversible damage. Also functions as a nucleotide deglycase able to repair glycated guanine in the free nucleotide pool (GTP, GDP, GMP, dGTP) and in DNA and RNA. Is thus involved in a major nucleotide repair system named guanine glycation repair (GG repair), dedicated to reversing methylglyoxal and glyoxal damage via nucleotide sanitization and direct nucleic acid repair. Also displays an apparent glyoxalase activity that in fact reflects its deglycase activity. Plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease; functions probably related to its primary function. It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells (By similarity). In pancreatic islets, involved in the maintenance of mitochondrial reactive oxygen species (ROS) levels and glucose homeostasis in an age- and diet dependent manner. Protects pancreatic beta cells from cell death induced by inflammatory and cytotoxic setting (By similarity). Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity (By similarity). In macrophages, interacts with the NADPH oxidase subunit NCF1 to direct NADPH oxidase-dependent ROS production, and protects against sepsis (By similarity).. | |
Protein Sequence | MASKRALVILAKGAEEMETVIPVDIMRRAGIKVTVAGLAGKDPVQCSRDVVICPDTSLEEAKTQGPYDVVVLPGGNLGAQNLSESALVKEILKEQENRKGLIAAICAGPTALLAHEVGFGCKVTSHPLAKDKMMNGSHYSYSESRVEKDGLILTSRGPGTSFEFALAIVEALSGKDMANQVKAPLVLKD | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MASKRALVI ------CCCCCEEEE | 24.61 | - | |
34 | Phosphorylation | RRAGIKVTVAGLAGK HHCCCEEEEECCCCC | 10.31 | 28689409 | |
46 | S-nitrosocysteine | AGKDPVQCSRDVVIC CCCCCCCCCCCEEEC | 3.52 | - | |
46 | S-palmitoylation | AGKDPVQCSRDVVIC CCCCCCCCCCCEEEC | 3.52 | - | |
46 | S-nitrosylation | AGKDPVQCSRDVVIC CCCCCCCCCCCEEEC | 3.52 | 22178444 | |
47 | Phosphorylation | GKDPVQCSRDVVICP CCCCCCCCCCEEECC | 17.90 | 28689409 | |
53 | S-nitrosocysteine | CSRDVVICPDTSLEE CCCCEEECCCCCHHH | 1.36 | - | |
53 | S-palmitoylation | CSRDVVICPDTSLEE CCCCEEECCCCCHHH | 1.36 | - | |
53 | S-nitrosylation | CSRDVVICPDTSLEE CCCCEEECCCCCHHH | 1.36 | 22178444 | |
67 | Phosphorylation | EAKTQGPYDVVVLPG HHHHCCCCCEEEECC | 28.35 | - | |
93 | Acetylation | ALVKEILKEQENRKG HHHHHHHHHHHCCCC | 64.11 | 22902405 | |
106 | S-palmitoylation | KGLIAAICAGPTALL CCHHHHHHCCHHHHH | 2.84 | - | |
106 | S-nitrosylation | KGLIAAICAGPTALL CCHHHHHHCCHHHHH | 2.84 | 22178444 | |
106 | Oxidation | KGLIAAICAGPTALL CCHHHHHHCCHHHHH | 2.84 | - | |
106 | Cysteine sulfinic acid (-SO2H) | KGLIAAICAGPTALL CCHHHHHHCCHHHHH | 2.84 | - | |
121 | S-nitrosocysteine | AHEVGFGCKVTSHPL HHHHCCCCEECCCCC | 2.75 | - | |
121 | S-nitrosylation | AHEVGFGCKVTSHPL HHHHCCCCEECCCCC | 2.75 | 22178444 | |
130 | Acetylation | VTSHPLAKDKMMNGS ECCCCCCCCCCCCCC | 66.61 | 22902405 | |
132 | Acetylation | SHPLAKDKMMNGSHY CCCCCCCCCCCCCCC | 39.06 | 22902405 | |
137 | Phosphorylation | KDKMMNGSHYSYSES CCCCCCCCCCCCCCC | 17.78 | 23984901 | |
139 | Phosphorylation | KMMNGSHYSYSESRV CCCCCCCCCCCCCCE | 15.82 | 23984901 | |
140 | Phosphorylation | MMNGSHYSYSESRVE CCCCCCCCCCCCCEE | 19.43 | 23984901 | |
141 | Phosphorylation | MNGSHYSYSESRVEK CCCCCCCCCCCCEEE | 14.86 | 23984901 | |
142 | Phosphorylation | NGSHYSYSESRVEKD CCCCCCCCCCCEEEC | 24.13 | 23984901 | |
144 | Phosphorylation | SHYSYSESRVEKDGL CCCCCCCCCEEECCE | 35.37 | 25575281 | |
148 | Acetylation | YSESRVEKDGLILTS CCCCCEEECCEEEEE | 54.99 | 22902405 | |
154 | Phosphorylation | EKDGLILTSRGPGTS EECCEEEEECCCCCC | 14.91 | 17564427 | |
155 | Phosphorylation | KDGLILTSRGPGTSF ECCEEEEECCCCCCH | 31.62 | 17564427 | |
182 | Succinylation | KDMANQVKAPLVLKD CCHHHHCCCCEEECC | 34.23 | - | |
182 | Succinylation | KDMANQVKAPLVLKD CCHHHHCCCCEEECC | 34.23 | - | |
188 | Acetylation | VKAPLVLKD------ CCCCEEECC------ | 54.64 | 22902405 | |
188 | Succinylation | VKAPLVLKD------ CCCCEEECC------ | 54.64 | 26843850 |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
130 | K | Sumoylation |
| - |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PARK7_RAT !! |
Kegg Drug | ||||||
---|---|---|---|---|---|---|
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...